general The Secretary shall maintain, and publish on a publicly available internet website, a list of measures established or adopted under this paragraph. Such list shall initially be published no later than June 1, 2024. (ii) Update The Secretary shall periodically evaluate measures, measure criteria, and how measures are applied by type of pharmacy and update the measures on the list under clause (i) to ensure such measures meet the requirements under subparagraph (A)(ii). (3) OIG reports on pharmacy performance measures (A) OIG study The Office of the Inspector General of the Department of Health and Human Services (in this paragraph referred to as the Inspector General ) shall conduct a study of the use of performance measures and other quality-related mechanisms in network pharmacy agreements and other relevant contracting arrangements among PDP sponsors offering a prescription drug plan, MA organizations offering a MA–PD plan, pharmacy benefit managers acting on behalf of such sponsors and organizations, and network pharmacies. Such study may include audits, reviews of relevant enforcement actions, consultation with relevant stakeholders, and other activities determined appropriate by the Inspector General, consistent with other provisions of law. Such study shall, to the extent feasible, include analysis of— (i) oversight and enforcement activities undertaken with respect to current statutory and regulatory requirements related to network pharmacy agreements, including under sections 423.505(b)(18) and 423.505(i) of title 42 of the Code of Federal Regulations (or any successor regulation) and under section 1860D–4(b)(1)(A)